Actively Recruiting
Distrupt Stiffness Trial
Led by University Hospital, Essen · Updated on 2025-08-19
40
Participants Needed
2
Research Sites
50 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Essen
Lead Sponsor
S
Shockwave Medical, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Typical symptoms of PAD include exercise-induced pain in the legs (known as intermittent claudication), which can significantly limit pain-free walking. In more advanced stages, pain may also occur at rest. Additionally, the development of chronic, hard-to-heal wounds-especially on the feet and toes-is possible. These wound healing impairments are caused by the insufficient supply of oxygen and nutrients to the affected tissues. The underlying cause of PAD is usually atherosclerosis, a pathological change in the vessel walls due to the accumulation of fats, calcium, and connective tissue. These deposits lead to stiffening and narrowing of the arteries, severely restricting blood flow. Major risk factors for the development of PAD include widespread chronic conditions such as diabetes mellitus, hyperlipidemia (elevated blood lipid levels, e.g., cholesterol), arterial hypertension (high blood pressure), obesity, and tobacco use. Various therapeutic options are available for the treatment of PAD. In addition to conservative therapy (such as supervised exercise training, pharmacological blood thinning, and risk factor management), interventional, minimally invasive treatment using catheter-based techniques is frequently employed. In such procedures, a thin catheter is guided through the vascular system to the affected area of the leg artery. Depending on the type and extent of the arterial narrowing or calcification, one of the following techniques may be applied: Balloon angioplasty: Dilation of the vessel using an inflatable balloon. Lithoplasty: Application of shockwaves to break down calcifications in the arterial wall.
CONDITIONS
Official Title
Distrupt Stiffness Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Peripheral artery disease
- Severe calcification classified as PACCS 2, 3, or 4
- Target lesions located in distal external iliac artery, common femoral artery, proximal superficial femoral artery, or popliteal artery
- Clinical diagnosis of chronic, symptomatic lower limb ischemia with Rutherford stages 2, 3, 4, or 5
- Planned peripheral intervention classified as TASC A to D
- Age between 18 and 85 years old
- Willingness to comply with all specified follow-up evaluations
- Signed written informed consent before any study procedures
You will not qualify if you...
- Target lesions that cannot be optimally visualized by ultrasound
- Instent restenosis at the lesion site
- Thrombolysis treatment within 72 hours before the procedure
- Aneurysm in the femoral or popliteal artery
- Presence of hepatic insufficiency, deep vein thrombosis, coagulation disorders, or current immunosuppressant therapy
- Unstable angina pectoris at enrollment
- Myocardial infarction or stroke within 30 days before the procedure
- Life expectancy less than 12 months
- Septicemia at enrollment
- Active infection at the procedure time except for infections of a lower extremity wound on the target limb
- Known or suspected allergies or contraindications to aspirin, clopidogrel, or heparin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
West German Heart and Vascular Center, Clinic for Cardiology and Vascular Medicine, Universtiy Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147
Not Yet Recruiting
2
University of Duisburg-Essen
Essen, Germany, 45147
Actively Recruiting
Research Team
C
Christos Rammos, Prof. Dr. med.
CONTACT
D
Daniel Messiha, Dr. med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here